Effect of statin therapy on SARS-CoV-2 infection-related

Aim: Assessing the effect of statin therapy at hospital admission for COVID-19 on in-hospital mortality. Methods and results: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic m...

Descripción completa

Detalles Bibliográficos
Autores: Masana, Luís, Correig, Eudald, Rodríguez-Borjabad, Cèlia, Anoro, Eva, Arroyo-Díaz, Juan Antonio, Jericó, Carlos, Pedragosa, Angels, Miret, Marcel·la, Näf, Silvia, Pardo, Anna, Perea, Verónica, Pérez-Bernalte, Rosa, Plana, Nuria, Ramírez-Montesinos, Rafael, Royuela, Meritxell, Soler, Cristina, Urquizu-Padilla, Maria, Pedro-Botet, Juan, The Stacov-Xula Research Group
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/47976
Acceso en línea:http://hdl.handle.net/10230/47976
http://dx.doi.org/10.1093/ehjcvp/pvaa128
Access Level:acceso abierto
Palabra clave:COVID-19
Cardiovascular risk
Mortality
SARS-CoV-2
Statins
id ES_ff30dc805966cd9f17c0d71c2ce95eb0
oai_identifier_str oai:recercat.cat:10230/47976
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effect of statin therapy on SARS-CoV-2 infection-relatedMasana, LuísCorreig, EudaldRodríguez-Borjabad, CèliaAnoro, EvaArroyo-Díaz, Juan AntonioJericó, CarlosPedragosa, AngelsMiret, Marcel·laNäf, SilviaPardo, AnnaPerea, VerónicaPérez-Bernalte, RosaPlana, NuriaRamírez-Montesinos, RafaelRoyuela, MeritxellSoler, CristinaUrquizu-Padilla, MariaMasana, LuísPedro-Botet, JuanThe Stacov-Xula Research GroupCOVID-19Cardiovascular riskMortalitySARS-CoV-2StatinsAim: Assessing the effect of statin therapy at hospital admission for COVID-19 on in-hospital mortality. Methods and results: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk.Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients (1234 men, 923 women; age: 67 y/o (IQR 54-78)) admitted to the hospital were retrieved from the clinical records in anonymized manner. 353 deaths occurred. 581 patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on statin therapy than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: p = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared to the GM non-statin group (17.4%; p = 0.045). The Cox model applied to the CSH function (HR = 0.58(CI: 0.39-0.89); p = 0.01) and the competing risks FG model (HR = 0.60(CI: 0.39-0.92); p = 0.02) suggest that statins are associated with reduced COVID-19-related mortality. Conclusions: A lower SARS-CoV-2 infection-related mortality was observed in patients treated with statin therapy prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19.Oxford University Press20212022info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/47976http://dx.doi.org/10.1093/ehjcvp/pvaa128reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésEuropean Heart Journal. 2022 Feb 16;8(2):157-64.© Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in European heart journal. Cardiovascular pharmacotherapy following peer review. The version of record Masana L, Correig E, Rodríguez-Borjabad C, Anoro E, Arroyo JA, Jericó C, Effect of statin therapy on SARS-CoV-2 infection-related. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-64, is available online at: https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa128/5949102, http://dx.doi.org/10.1093/ehjcvp/pvaa128info:eu-repo/semantics/openAccessoai:recercat.cat:10230/479762026-05-29T05:05:01Z
dc.title.none.fl_str_mv Effect of statin therapy on SARS-CoV-2 infection-related
title Effect of statin therapy on SARS-CoV-2 infection-related
spellingShingle Effect of statin therapy on SARS-CoV-2 infection-related
Masana, Luís
COVID-19
Cardiovascular risk
Mortality
SARS-CoV-2
Statins
title_short Effect of statin therapy on SARS-CoV-2 infection-related
title_full Effect of statin therapy on SARS-CoV-2 infection-related
title_fullStr Effect of statin therapy on SARS-CoV-2 infection-related
title_full_unstemmed Effect of statin therapy on SARS-CoV-2 infection-related
title_sort Effect of statin therapy on SARS-CoV-2 infection-related
dc.creator.none.fl_str_mv Masana, Luís
Correig, Eudald
Rodríguez-Borjabad, Cèlia
Anoro, Eva
Arroyo-Díaz, Juan Antonio
Jericó, Carlos
Pedragosa, Angels
Miret, Marcel·la
Näf, Silvia
Pardo, Anna
Perea, Verónica
Pérez-Bernalte, Rosa
Plana, Nuria
Ramírez-Montesinos, Rafael
Royuela, Meritxell
Soler, Cristina
Urquizu-Padilla, Maria
Masana, Luís
Pedro-Botet, Juan
The Stacov-Xula Research Group
author Masana, Luís
author_facet Masana, Luís
Correig, Eudald
Rodríguez-Borjabad, Cèlia
Anoro, Eva
Arroyo-Díaz, Juan Antonio
Jericó, Carlos
Pedragosa, Angels
Miret, Marcel·la
Näf, Silvia
Pardo, Anna
Perea, Verónica
Pérez-Bernalte, Rosa
Plana, Nuria
Ramírez-Montesinos, Rafael
Royuela, Meritxell
Soler, Cristina
Urquizu-Padilla, Maria
Pedro-Botet, Juan
The Stacov-Xula Research Group
author_role author
author2 Correig, Eudald
Rodríguez-Borjabad, Cèlia
Anoro, Eva
Arroyo-Díaz, Juan Antonio
Jericó, Carlos
Pedragosa, Angels
Miret, Marcel·la
Näf, Silvia
Pardo, Anna
Perea, Verónica
Pérez-Bernalte, Rosa
Plana, Nuria
Ramírez-Montesinos, Rafael
Royuela, Meritxell
Soler, Cristina
Urquizu-Padilla, Maria
Pedro-Botet, Juan
The Stacov-Xula Research Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
Cardiovascular risk
Mortality
SARS-CoV-2
Statins
topic COVID-19
Cardiovascular risk
Mortality
SARS-CoV-2
Statins
description Aim: Assessing the effect of statin therapy at hospital admission for COVID-19 on in-hospital mortality. Methods and results: Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk.Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients (1234 men, 923 women; age: 67 y/o (IQR 54-78)) admitted to the hospital were retrieved from the clinical records in anonymized manner. 353 deaths occurred. 581 patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on statin therapy than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: p = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared to the GM non-statin group (17.4%; p = 0.045). The Cox model applied to the CSH function (HR = 0.58(CI: 0.39-0.89); p = 0.01) and the competing risks FG model (HR = 0.60(CI: 0.39-0.92); p = 0.02) suggest that statins are associated with reduced COVID-19-related mortality. Conclusions: A lower SARS-CoV-2 infection-related mortality was observed in patients treated with statin therapy prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/47976
http://dx.doi.org/10.1093/ehjcvp/pvaa128
url http://hdl.handle.net/10230/47976
http://dx.doi.org/10.1093/ehjcvp/pvaa128
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv European Heart Journal. 2022 Feb 16;8(2):157-64.
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425752203591680
score 15,812455

Similares en LA Referencia